# EDGAR Filing Document

**Accession Number:** 0001100682
**File Stem:** 0001628280-25-052484
**Filing Date:** 2025-11
**Character Count:** 4975
**Document Hash:** dd7116aa3769e878675d30e56715cee1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-052484.hdr.sgml**: 20251117

**ACCESSION NUMBER**: 0001628280-25-052484

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251114

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20251117

**DATE AS OF CHANGE**: 20251117

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- **CENTRAL INDEX KEY:** 0001100682
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 061397316
- **FISCAL YEAR END:** 1227

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15943
- **FILM NUMBER:** 251489395

**BUSINESS ADDRESS:**
- **STREET 1:** 251 BALLARDVALE ST
- **CITY:** WILMINGTON
- **STATE:** MA
- **ZIP:** 01887
- **BUSINESS PHONE:** 781-222-6000

**MAIL ADDRESS:**
- **STREET 1:** 251 BALLARDVALE ST
- **CITY:** WILMINGTON
- **STATE:** MA
- **ZIP:** 01887

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHARLES RIVER LABORATORIES INTERNATIONAL INC
- **DATE OF NAME CHANGE:** 20000605

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHARLES RIVER LABORATORIES HOLDINGS INC
- **DATE OF NAME CHANGE:** 19991208

?xml version='1.0' encoding='ASCII'? crl-20251114

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**November 14, 2025** 

Date of Report (Date of earliest event reported)

**CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** 

(Exact Name of Registrant as Specified in Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-15943** | **06-1397316** |
| (State or Other<br>Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer<br>Identification No.) |

---

**251 Ballardvale Street** 

**Wilmington, Massachusetts 01887** 

(Address of Principal Executive Offices) (Zip Code)

**781-222-6000** 

(Registrant's Telephone Number, including Area Code)

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common stock, $0.01 par value | CRL | New York Stock Exchange |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 8.01 Other Events**

As previously disclosed, on May 16, 2023, Charles River Laboratories International, Inc., (Company) received an inquiry from the Enforcement Division of the U.S. Securities and Exchange Commission (SEC) requesting it to voluntarily provide information, subsequently augmented with a document subpoena and additional inquiries, primarily related to the sourcing of non-human primates and related disclosures. In addition, the Company's Audit Committee retained counsel to conduct an independent investigation into certain issues raised in the investigation.

On November 14, 2025, the SEC's Division of Enforcement (Division) notified the Company that it concluded its investigation and, based on the information available to the Division, it does not intend to recommend an enforcement action by the SEC against the Company. Similarly, the Company's independent investigation into these matters has also concluded, with no material findings.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** |
| Date: | November 17, 2025 | By: | /s/ Matthew L. Daniel |
|  |  |  | Matthew L. Daniel, Corporate Senior Vice President, |
|  |  |  | General Counsel, Corporate Secretary & Chief Compliance Officer |

---